Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Haemoglobin-based erythrocyte transfusion substitutes.

T Standl1

  • 1Dept. of Anesthesiology, University Hospital Hamburg-Eppendorf, Martini Strasse 52, Germany. standl@uke.uni-hamburg.de

Expert Opinion on Biological Therapy
|December 1, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epidural needle insertion : A large registry analysis.

Der Anaesthesist·2018
Same author

[Neuraxial anaesthesia and NOACs].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2017
Same author

Tunnelling of thoracic epidural catheters is associated with fewer catheter-related infections: a retrospective registry analysis.

British journal of anaesthesia·2016
Same author

[Anesthesia in obstetrics: Tried and trusted methods, current standards and new challenges].

Der Anaesthesist·2016
Same author

Obesity in regional anesthesia--a risk factor for peripheral catheter-related infections.

Acta anaesthesiologica Scandinavica·2015
Same author

[Do not harm anybody].

Der Anaesthesist·2015

Hemoglobin-based oxygen carriers (HBOCs) offer an alternative to blood transfusions, providing oxygen delivery without cross-matching. While some trials faced setbacks, HBOC-201 shows promise in reducing transfusions and improving tissue oxygenation.

Area of Science:

  • Biomedical Engineering
  • Hematology
  • Pharmacology

Background:

  • Allogeneic blood products carry infectious and immunosuppressive risks.
  • Increased demand for blood necessitates alternative erythrocyte transfusion strategies.
  • Hemoglobin-based oxygen carriers (HBOCs) are being developed as safer alternatives.

Purpose of the Study:

  • To evaluate the effectiveness and tolerability of HBOCs as erythrocyte substitutes.
  • To explore the potential of HBOCs in improving tissue oxygenation.
  • To assess the role of HBOCs in managing peri-operative anemia and conditions with impaired perfusion.

Main Methods:

  • Review of animal and clinical studies involving various HBOC formulations, including DCLHb and HBOC-201.
  • Analysis of Phase III studies and clinical trials in surgical, cardiac surgery, sepsis, and tumor patients.

Related Experiment Videos

  • Investigation of HBOCs' oxygen-donating properties and their advantages over red blood cells in specific physiological conditions.

    • Main Results:

    • HBOCs demonstrate effectiveness and tolerability in numerous preclinical and clinical studies.
    • HBOC-201 has shown success in avoiding or reducing allogeneic blood transfusions in peri-operative settings and received approval in South Africa.
    • HBOCs function as potent oxygen donors, enhancing tissue oxygenation and offering advantages in cases of ischemia or arterial stenosis.

    Conclusions:

    • HBOCs represent a promising therapeutic strategy for oxygen delivery, with potential applications beyond simple red blood cell substitution.
    • Further research is needed to confirm the benefits of HBOCs in patients with impaired perfusion, such as stroke or myocardial infarction.
    • HBOCs are poised to become important oxygen-delivering drugs with diverse indications, particularly in managing bleeding and improving oxygenation.